The following is a summary of the Arcturus Therapeutics Holdings Inc. (ARCT) Q3 2024 Earnings Call Transcript:
Financial Performance:
Arcturus reported Q3 2024 revenue of $41.7 million, a slight decrease from $45.1 million in Q3 2023.
Total operating expenses decreased to $52.4 million from $64.5 million in Q3 2023.
R&D expenses were $39.1 million in Q3 2024, down from $51.1 million in Q3 2023.The company recorded a net loss of $6.9 million, improving from a net loss of $16.2 million in Q3 2023.
Business Progress:
Arcturus launched KOSTAIVE, a self-amplifying mRNA COVID-19 vaccine, commercially in Japan.
Positive Phase 3 results for ARCT-2303 and ongoing regulatory submissions.
FDA clearance for a Phase 2 study of ARCT-032, an inhaled mRNA therapy for cystic fibrosis.
Expansion of the Phase 2 clinical program for ARCT-810 (OTC deficiency) in the U.S.
Continued development and strategic focus on mRNA therapeutics, specifically targeting respiratory illnesses and other diseases.
Opportunities:
Expansion of manufacturing capabilities through the strategic asset Arcalis to support the future production and potential commercialization of ARCT-032 for cystic fibrosis.
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
